Corrigendum: Downregulation of ATXN3 enhances the sensitivity to AKT inhibitors (Perifosine or MK-2206), but decreases the sensitivity to chemotherapeutic drugs (etoposide or cisplatin) in neuroblastoma cells

Detalles Bibliográficos
Autores principales: Gong, Baocheng, Zhang, Jinhua, Hua, Zhongyan, Liu, Zhihui, Thiele, Carol J., Li, Zhijie
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2022
Materias:
Oncology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9382292/
https://www.ncbi.nlm.nih.gov/pubmed/35992874
http://dx.doi.org/10.3389/fonc.2022.984514
_version_ 1784769256650440704
author Gong, Baocheng
Zhang, Jinhua
Hua, Zhongyan
Liu, Zhihui
Thiele, Carol J.
Li, Zhijie
author_facet Gong, Baocheng
Zhang, Jinhua
Hua, Zhongyan
Liu, Zhihui
Thiele, Carol J.
Li, Zhijie
author_sort Gong, Baocheng
collection PubMed
description
format Online
Article
Text
id pubmed-9382292
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-93822922022-08-18 Corrigendum: Downregulation of ATXN3 enhances the sensitivity to AKT inhibitors (Perifosine or MK-2206), but decreases the sensitivity to chemotherapeutic drugs (etoposide or cisplatin) in neuroblastoma cells Gong, Baocheng Zhang, Jinhua Hua, Zhongyan Liu, Zhihui Thiele, Carol J. Li, Zhijie Front Oncol Oncology Frontiers Media S.A. 2022-08-03 /pmc/articles/PMC9382292/ /pubmed/35992874 http://dx.doi.org/10.3389/fonc.2022.984514 Text en Copyright © 2022 Gong, Zhang, Hua, Liu, Thiele and Li https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Oncology
Gong, Baocheng
Zhang, Jinhua
Hua, Zhongyan
Liu, Zhihui
Thiele, Carol J.
Li, Zhijie
Corrigendum: Downregulation of ATXN3 enhances the sensitivity to AKT inhibitors (Perifosine or MK-2206), but decreases the sensitivity to chemotherapeutic drugs (etoposide or cisplatin) in neuroblastoma cells
title Corrigendum: Downregulation of ATXN3 enhances the sensitivity to AKT inhibitors (Perifosine or MK-2206), but decreases the sensitivity to chemotherapeutic drugs (etoposide or cisplatin) in neuroblastoma cells
title_full Corrigendum: Downregulation of ATXN3 enhances the sensitivity to AKT inhibitors (Perifosine or MK-2206), but decreases the sensitivity to chemotherapeutic drugs (etoposide or cisplatin) in neuroblastoma cells
title_fullStr Corrigendum: Downregulation of ATXN3 enhances the sensitivity to AKT inhibitors (Perifosine or MK-2206), but decreases the sensitivity to chemotherapeutic drugs (etoposide or cisplatin) in neuroblastoma cells
title_full_unstemmed Corrigendum: Downregulation of ATXN3 enhances the sensitivity to AKT inhibitors (Perifosine or MK-2206), but decreases the sensitivity to chemotherapeutic drugs (etoposide or cisplatin) in neuroblastoma cells
title_short Corrigendum: Downregulation of ATXN3 enhances the sensitivity to AKT inhibitors (Perifosine or MK-2206), but decreases the sensitivity to chemotherapeutic drugs (etoposide or cisplatin) in neuroblastoma cells
title_sort corrigendum: downregulation of atxn3 enhances the sensitivity to akt inhibitors (perifosine or mk-2206), but decreases the sensitivity to chemotherapeutic drugs (etoposide or cisplatin) in neuroblastoma cells
topic Oncology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9382292/
https://www.ncbi.nlm.nih.gov/pubmed/35992874
http://dx.doi.org/10.3389/fonc.2022.984514
work_keys_str_mv AT gongbaocheng corrigendumdownregulationofatxn3enhancesthesensitivitytoaktinhibitorsperifosineormk2206butdecreasesthesensitivitytochemotherapeuticdrugsetoposideorcisplatininneuroblastomacells
AT zhangjinhua corrigendumdownregulationofatxn3enhancesthesensitivitytoaktinhibitorsperifosineormk2206butdecreasesthesensitivitytochemotherapeuticdrugsetoposideorcisplatininneuroblastomacells
AT huazhongyan corrigendumdownregulationofatxn3enhancesthesensitivitytoaktinhibitorsperifosineormk2206butdecreasesthesensitivitytochemotherapeuticdrugsetoposideorcisplatininneuroblastomacells
AT liuzhihui corrigendumdownregulationofatxn3enhancesthesensitivitytoaktinhibitorsperifosineormk2206butdecreasesthesensitivitytochemotherapeuticdrugsetoposideorcisplatininneuroblastomacells
AT thielecarolj corrigendumdownregulationofatxn3enhancesthesensitivitytoaktinhibitorsperifosineormk2206butdecreasesthesensitivitytochemotherapeuticdrugsetoposideorcisplatininneuroblastomacells
AT lizhijie corrigendumdownregulationofatxn3enhancesthesensitivitytoaktinhibitorsperifosineormk2206butdecreasesthesensitivitytochemotherapeuticdrugsetoposideorcisplatininneuroblastomacells

Ejemplares similares